|
US9464124B2
(en)
|
2011-09-12 |
2016-10-11 |
Moderna Therapeutics, Inc. |
Engineered nucleic acids and methods of use thereof
|
|
CA2892529C
(en)
|
2012-11-26 |
2023-04-25 |
Moderna Therapeutics, Inc. |
Terminally modified rna
|
|
US20140200261A1
(en)
|
2013-01-17 |
2014-07-17 |
Moderna Therapeutics, Inc. |
Signal-sensor polynucleotides for the alteration of cellular phenotypes
|
|
EP3052106A4
(en)
|
2013-09-30 |
2017-07-19 |
ModernaTX, Inc. |
Polynucleotides encoding immune modulating polypeptides
|
|
CA3177878A1
(en)
|
2014-04-23 |
2015-10-29 |
Modernatx, Inc. |
Nucleic acid vaccines
|
|
ES2946969T3
(es)
|
2014-12-12 |
2023-07-28 |
CureVac SE |
Moléculas de ácido nucleico artificiales para una expresión proteica mejorada
|
|
EP3233132A4
(en)
*
|
2014-12-19 |
2018-06-27 |
Modernatx, Inc. |
Terminal modifications of polynucleotides
|
|
MA42502A
(fr)
|
2015-07-21 |
2018-05-30 |
Modernatx Inc |
Vaccins contre une maladie infectieuse
|
|
US11364292B2
(en)
|
2015-07-21 |
2022-06-21 |
Modernatx, Inc. |
CHIKV RNA vaccines
|
|
MA42543A
(fr)
|
2015-07-30 |
2018-06-06 |
Modernatx Inc |
Arn épitope peptidiques concatémériques
|
|
US11564893B2
(en)
|
2015-08-17 |
2023-01-31 |
Modernatx, Inc. |
Methods for preparing particles and related compositions
|
|
AU2016336344A1
(en)
|
2015-10-05 |
2018-04-19 |
Modernatx, Inc. |
Methods for therapeutic administration of messenger ribonucleic acid drugs
|
|
TW201729838A
(zh)
|
2015-10-22 |
2017-09-01 |
現代公司 |
用於水痘帶狀疱疹病毒 (vzv)之核酸疫苗
|
|
PT3718565T
(pt)
|
2015-10-22 |
2022-07-20 |
Modernatx Inc |
Vacinas contra vírus respiratórios
|
|
AU2016342376A1
(en)
|
2015-10-22 |
2018-06-07 |
Modernatx, Inc. |
Sexually transmitted disease vaccines
|
|
CA3002922A1
(en)
|
2015-10-22 |
2017-04-27 |
Modernatx, Inc. |
Human cytomegalovirus vaccine
|
|
WO2017070624A1
(en)
|
2015-10-22 |
2017-04-27 |
Modernatx, Inc. |
Tropical disease vaccines
|
|
DK3386484T3
(da)
|
2015-12-10 |
2022-07-04 |
Modernatx Inc |
Sammensætninger og fremgangsmåder til afgivelse af terapeutiske midler
|
|
IL262728B2
(en)
|
2016-05-06 |
2023-10-01 |
Astrazeneca Ab |
Oligonucleotides conjugated to the GLP-1 receptor ligand complex and their uses
|
|
WO2017201342A1
(en)
*
|
2016-05-18 |
2017-11-23 |
Modernatx, Inc. |
Polynucleotides encoding jagged1 for the treatment of alagille syndrome
|
|
WO2017201347A1
(en)
*
|
2016-05-18 |
2017-11-23 |
Modernatx, Inc. |
Polynucleotides encoding cystic fibrosis transmembrane conductance regulator for the treatment of cystic fibrosis
|
|
KR20190026819A
(ko)
|
2016-07-07 |
2019-03-13 |
루비우스 테라퓨틱스, 아이엔씨. |
외인성 rna를 발현하는 치료용 세포 시스템과 관련된 조성물 및 방법
|
|
CN116837052A
(zh)
|
2016-09-14 |
2023-10-03 |
摩登纳特斯有限公司 |
高纯度rna组合物及其制备方法
|
|
EP3528821A4
(en)
|
2016-10-21 |
2020-07-01 |
ModernaTX, Inc. |
HUMAN CYTOMEGALOVIRUS VACCINE
|
|
WO2018089851A2
(en)
|
2016-11-11 |
2018-05-17 |
Modernatx, Inc. |
Influenza vaccine
|
|
CN110121558B
(zh)
*
|
2016-11-28 |
2023-06-13 |
日商那帕洁制药股份有限公司 |
化学修饰siRNA
|
|
US11103578B2
(en)
|
2016-12-08 |
2021-08-31 |
Modernatx, Inc. |
Respiratory virus nucleic acid vaccines
|
|
WO2018111967A1
(en)
|
2016-12-13 |
2018-06-21 |
Modernatx, Inc. |
Rna affinity purification
|
|
WO2018170270A1
(en)
|
2017-03-15 |
2018-09-20 |
Modernatx, Inc. |
Varicella zoster virus (vzv) vaccine
|
|
EP3595713A4
(en)
|
2017-03-15 |
2021-01-13 |
ModernaTX, Inc. |
Respiratory syncytial virus vaccine
|
|
WO2018170256A1
(en)
|
2017-03-15 |
2018-09-20 |
Modernatx, Inc. |
Herpes simplex virus vaccine
|
|
US11576961B2
(en)
|
2017-03-15 |
2023-02-14 |
Modernatx, Inc. |
Broad spectrum influenza virus vaccine
|
|
EP3595676A4
(en)
|
2017-03-17 |
2021-05-05 |
Modernatx, Inc. |
RNA VACCINES AGAINST ZOONOSES
|
|
MA48047A
(fr)
|
2017-04-05 |
2020-02-12 |
Modernatx Inc |
Réduction ou élimination de réponses immunitaires à des protéines thérapeutiques administrées par voie non intraveineuse, par exemple par voie sous-cutanée
|
|
KR102050870B1
(ko)
*
|
2017-04-06 |
2019-12-02 |
포항공과대학교 산학협력단 |
무항생제 플라스미드 유지 시스템에서 플라스미드 카피 수의 정량적 조절 방법
|
|
EP3621637A1
(en)
|
2017-05-09 |
2020-03-18 |
Fundacion para la Investigacion Medica Aplicada |
Human porphobilinogen deaminase derived proteins and polynucleotides and uses thereof
|
|
WO2018232357A1
(en)
|
2017-06-15 |
2018-12-20 |
Modernatx, Inc. |
Rna formulations
|
|
EP3668971B8
(en)
|
2017-08-18 |
2024-05-29 |
ModernaTX, Inc. |
Rna polymerase variants
|
|
EP3668979A4
(en)
|
2017-08-18 |
2021-06-02 |
Modernatx, Inc. |
METHOD OF HPLC ANALYSIS
|
|
MA49914A
(fr)
|
2017-08-18 |
2021-04-21 |
Modernatx Inc |
Procédés analytiques par hplc
|
|
MX2020002348A
(es)
|
2017-08-31 |
2020-10-08 |
Modernatx Inc |
Métodos de elaboración de nanopartículas lipídicas.
|
|
GB201714430D0
(en)
|
2017-09-07 |
2017-10-25 |
Micol Romain |
Compositions and processes for targeted delivery and expression and modulation of therapeutic components in tissue
|
|
US10653767B2
(en)
|
2017-09-14 |
2020-05-19 |
Modernatx, Inc. |
Zika virus MRNA vaccines
|
|
CN119876131A
(zh)
*
|
2017-11-08 |
2025-04-25 |
Ionis制药公司 |
Glp-1受体配体部分缀合的寡核苷酸及其用途
|
|
CA3086180A1
(en)
|
2017-12-22 |
2019-06-27 |
North Carolina State University |
Polymeric fluorophores, compositions comprising the same, and methods of preparing and using the same
|
|
US11911453B2
(en)
|
2018-01-29 |
2024-02-27 |
Modernatx, Inc. |
RSV RNA vaccines
|
|
CA3091543A1
(en)
*
|
2018-02-19 |
2019-08-22 |
Combined Therapeutics, Inc. |
Compositions and methods for organ-protective expression and modulation of coding ribonucleic acids
|
|
WO2020061284A1
(en)
|
2018-09-19 |
2020-03-26 |
Modernatx, Inc. |
Peg lipids and uses thereof
|
|
EP4509118A3
(en)
|
2018-09-19 |
2025-05-14 |
ModernaTX, Inc. |
High-purity peg lipids and uses thereof
|
|
JP2022501367A
(ja)
|
2018-09-20 |
2022-01-06 |
モデルナティエックス インコーポレイテッドModernaTX, Inc. |
脂質ナノ粒子の調製及びその投与方法
|
|
US12331320B2
(en)
|
2018-10-10 |
2025-06-17 |
The Research Foundation For The State University Of New York |
Genome edited cancer cell vaccines
|
|
US11351242B1
(en)
|
2019-02-12 |
2022-06-07 |
Modernatx, Inc. |
HMPV/hPIV3 mRNA vaccine composition
|
|
CN113795579A
(zh)
|
2019-02-20 |
2021-12-14 |
摩登纳特斯有限公司 |
用于共转录加帽的rna聚合酶变体
|
|
US11851694B1
(en)
|
2019-02-20 |
2023-12-26 |
Modernatx, Inc. |
High fidelity in vitro transcription
|
|
US12460259B2
(en)
|
2019-03-11 |
2025-11-04 |
Modernatx, Inc. |
Fed-batch in vitro transcription process
|
|
WO2020190750A1
(en)
|
2019-03-15 |
2020-09-24 |
Modernatx, Inc. |
Hiv rna vaccines
|
|
WO2020204130A1
(ja)
*
|
2019-04-05 |
2020-10-08 |
国立大学法人京都大学 |
Ｒｎａのキャッピング方法、修飾ｒｎａの製造方法、及び修飾ｒｎａ
|
|
US20220233722A1
(en)
|
2019-07-02 |
2022-07-28 |
Fundacion Para La Investigacion Medica Aplicada |
cPLA2e INDUCING AGENTS AND USES THEREOF
|
|
CN118490818A
(zh)
|
2020-04-22 |
2024-08-16 |
生物技术欧洲股份公司 |
冠状病毒疫苗
|
|
IL300247A
(en)
|
2020-07-31 |
2023-03-01 |
Combined Therapeutics Inc |
Compositions and methods for improving vaccination
|
|
US11406703B2
(en)
|
2020-08-25 |
2022-08-09 |
Modernatx, Inc. |
Human cytomegalovirus vaccine
|
|
WO2022066757A1
(en)
*
|
2020-09-23 |
2022-03-31 |
Myeloid Therapeutics, Inc. |
Improved methods and compositions for expression of nucleic acids in cells
|
|
EP4274607A1
(en)
|
2021-01-11 |
2023-11-15 |
ModernaTX, Inc. |
Seasonal rna influenza virus vaccines
|
|
US11524023B2
(en)
|
2021-02-19 |
2022-12-13 |
Modernatx, Inc. |
Lipid nanoparticle compositions and methods of formulating the same
|
|
US20220363937A1
(en)
|
2021-05-14 |
2022-11-17 |
Armstrong World Industries, Inc. |
Stabilization of antimicrobial coatings
|
|
AU2022297171A1
(en)
*
|
2021-06-24 |
2024-01-18 |
Hanmi Pharm. Co., Ltd. |
Non-natural 5’-untranslated region and 3’-untranslated region and use thereof
|
|
US20240325426A1
(en)
*
|
2021-06-30 |
2024-10-03 |
Kyowa Kirin Co., Ltd. |
Polynucleotide and pharmaceutical composition
|
|
JP7689238B2
(ja)
*
|
2021-07-27 |
2025-06-05 |
エスケー バイオサイエンス カンパニー リミテッド |
タンパク質発現のためのｍＲＮＡ、及びそのためのテンプレート
|
|
KR20240090727A
(ko)
|
2021-10-22 |
2024-06-21 |
세일 바이오메디슨스, 인크. |
Mrna 백신 조성물
|
|
CA3238764A1
(en)
|
2021-11-23 |
2023-06-01 |
Siddharth Patel |
A bacteria-derived lipid composition and use thereof
|
|
US12186387B2
(en)
|
2021-11-29 |
2025-01-07 |
BioNTech SE |
Coronavirus vaccine
|
|
JP2025500373A
(ja)
|
2021-12-20 |
2025-01-09 |
セイル バイオメディシンズ インコーポレイテッド |
Ｍｒｎａ治療用組成物
|
|
WO2023177904A1
(en)
|
2022-03-18 |
2023-09-21 |
Modernatx, Inc. |
Sterile filtration of lipid nanoparticles and filtration analysis thereof for biological applications
|
|
KR20250017230A
(ko)
|
2022-05-25 |
2025-02-04 |
플래그쉽 파이어니어링 이노베이션스 Vii, 엘엘씨 |
사이토카인을 조절하기 위한 조성물 및 방법
|
|
EP4532765A2
(en)
|
2022-05-25 |
2025-04-09 |
Flagship Pioneering Innovations VII, LLC |
Compositions and methods for modulation of immune responses
|
|
EP4640849A2
(en)
|
2022-05-25 |
2025-10-29 |
Flagship Pioneering Innovations VII, LLC |
Compositions and methods for modulating genetic drivers
|
|
KR20250019772A
(ko)
|
2022-05-25 |
2025-02-11 |
플래그쉽 파이어니어링 이노베이션스 Vii, 엘엘씨 |
종양 억제인자 및 발암유전자를 조절하기 위한 조성물 및 방법
|
|
CA3254388A1
(en)
|
2022-05-25 |
2023-11-30 |
Flagship Pioneering Innovations Vii, Llc |
COMPOSITIONS AND METHODS OF MODULATING TRAFFIC FACTORS
|
|
US11878055B1
(en)
|
2022-06-26 |
2024-01-23 |
BioNTech SE |
Coronavirus vaccine
|
|
WO2024035733A1
(en)
*
|
2022-08-08 |
2024-02-15 |
The Curators Of The University Of Missouri |
Fasl-modified plg scaffolds enhances differentiation of stem cell derived beta cells
|
|
WO2024044147A1
(en)
|
2022-08-23 |
2024-02-29 |
Modernatx, Inc. |
Methods for purification of ionizable lipids
|
|
EP4615424A1
(en)
|
2022-11-10 |
2025-09-17 |
Sail Biomedicines, Inc. |
Rna compositions comprising lipid nanoparticles or lipid reconstructed natural messenger packs
|
|
TW202430215A
(zh)
|
2022-12-14 |
2024-08-01 |
美商旗艦先鋒創新有限責任（Ｖｉｉ）公司 |
用於將治療劑遞送至骨之組成物和方法
|
|
WO2024159172A1
(en)
|
2023-01-27 |
2024-08-02 |
Senda Biosciences, Inc. |
A modified lipid composition and uses thereof
|
|
WO2024220712A2
(en)
|
2023-04-19 |
2024-10-24 |
Sail Biomedicines, Inc. |
Vaccine compositions
|
|
WO2024220625A1
(en)
|
2023-04-19 |
2024-10-24 |
Sail Biomedicines, Inc. |
Delivery of polynucleotides from lipid nanoparticles comprising rna and ionizable lipids
|
|
WO2024220752A2
(en)
|
2023-04-19 |
2024-10-24 |
Sail Biomedicines, Inc. |
Rna therapeutic compositions
|
|
WO2024238726A1
(en)
|
2023-05-16 |
2024-11-21 |
Omega Therapeutics, Inc. |
Methods and compositions for modulating methylation of a target gene
|
|
WO2024238723A1
(en)
|
2023-05-16 |
2024-11-21 |
Omega Therapeutics, Inc. |
Methods and compositions for modulating pcsk9 expression
|
|
WO2025019742A1
(en)
|
2023-07-19 |
2025-01-23 |
Omega Therapeutics, Inc. |
Methods and compositions for modulating ctnnb1 expression
|
|
KR20250047639A
(ko)
*
|
2023-09-27 |
2025-04-04 |
한미약품 주식회사 |
비천연 5'비번역 영역 및 그의 용도
|
|
WO2025194138A1
(en)
|
2024-03-14 |
2025-09-18 |
Tessera Therapeutics, Inc. |
St1cas9 compositions and methods for modulating a genome
|
|
WO2025235563A1
(en)
|
2024-05-07 |
2025-11-13 |
Omega Therapeutics, Inc. |
Epigenetic modulation for upregulation of genes
|